Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,552
  • Shares Outstanding, K 45,728
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,880 K
  • 60-Month Beta 1.85
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.64
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.32
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/27/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.13
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.61 +5.42%
on 02/27/20
1.22 -47.54%
on 02/05/20
-0.26 (-29.06%)
since 01/27/20
3-Month
0.61 +5.42%
on 02/27/20
1.22 -47.54%
on 02/05/20
-0.39 (-37.86%)
since 11/27/19
52-Week
0.61 +5.42%
on 02/27/20
3.15 -79.68%
on 04/22/19
-0.71 (-52.59%)
since 02/27/19

Most Recent Stories

More News
WPD Pharmaceuticals' Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD"), a clinical stage pharmaceutical company is pleased to provide an update on the clinical drug studies of Annamycin in Acute Myeloid...

WBIO.CN : 1.070 (-2.73%)
MBRX : 0.64 (-7.25%)
Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 0.64 (-7.25%)
WPD Pharmaceuticals' STAT3 Inhibitor Received FDA Approval of IND Status in Pediatric Brain Cancer Trial

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD"), a clinical stage pharmaceutical company is pleased to provide an update on its WP1066 drug in the treatment of pediatric brain...

WBIO.CN : 1.070 (-2.73%)
MBRX : 0.64 (-7.25%)
WPD Pharmaceuticals' WP1220 Drug Demonstrates Median Reduction of 56% in Skin Cancer Lesions in Clinical Trials

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD"), a clinical stage pharmaceutical company, in collaboration with license partner, Moleculin Biotech, Inc. ("Moleculin")(Nasdaq: MBRX)...

WBIO.CN : 1.070 (-2.73%)
MBRX : 0.64 (-7.25%)
Moleculin Presents Clinical Trial Data Demonstrating a Median Reduction of 56% in Skin Cancer Lesions

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced the final...

MBRX : 0.64 (-7.25%)
Moleculin Announces $6.0 Million Registered Direct Offering

Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 0.64 (-7.25%)
R&D Leading to Supported Progress for Treating Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) research has seen great progress with more researchers are now studying the causes, diagnosis, and treatment of Acute myeloid leukemia (AML) at many medical centers, university...

MBRX : 0.64 (-7.25%)
LJPC : 6.73 (-2.89%)
INSM : 24.20 (-8.05%)
TEVA : 12.21 (-6.22%)
PBYI : 10.03 (-5.47%)
Moleculin to Seek Accelerated FDA Approval and Plans for Pivotal Phase 2 AML Trial

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 0.64 (-7.25%)
WPD Pharmaceuticals' Annamycin Drug Received FDA Approval of Fast Track Designation

WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the "Company" or "WPD"), a clinical stage pharmaceutical company, is pleased to provide an update on its Annamycin Drug. Through its development partner,...

WBIO.CN : 1.070 (-2.73%)
MBRX : 0.64 (-7.25%)
Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 0.64 (-7.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade MBRX with:

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

2nd Resistance Point 0.76
1st Resistance Point 0.72
Last Price 0.64
1st Support Level 0.66
2nd Support Level 0.64

See More

52-Week High 3.15
Fibonacci 61.8% 2.18
Fibonacci 50% 1.88
Fibonacci 38.2% 1.58
Last Price 0.64
52-Week Low 0.61

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar